Shanghai, China BioTrack Capital is the famous VC, which was founded in 2016. The venture was found in Asia in China. The main department of described VC is located in the Shanghai.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the BioTrack Capital, startups are often financed by Vision Plus Capital, Morningside Venture Capital, CASH Capital. The meaningful sponsors for the fund in investment in the same round are CASH Capital, Fosun Group, China Creation Ventures (CCV). In the next rounds fund is usually obtained by China Creation Ventures (CCV), CASH Capital, ZWC Partners.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Biopharma, Wellness. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Haihe Biopharma, HC Scientific.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. The important activity for fund was in 2019.
Related Funds
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Rona Therapeutics | $35M | 19 Jul 2024 | Shanghai, Shanghai, China | ||
Brise Pharma | $20M | 22 Apr 2024 | Shanghai, Shanghai, China | ||
Shenluo Medical | 18 Apr 2024 | Hangzhou, Zhejiang, China | |||
Yuce Biotechnology | 22 Mar 2024 | Suzhou, Jiangsu, China | |||
OnCusp Therapeutics | $100M | 04 Jan 2024 | New York, New York, United States | ||
Salus BioMed | 01 Dec 2023 | Shenzhen, Guangdong, China | |||
Acchrom Tech | $15M | 29 May 2023 | Huairou, Beijing, China | ||
Reforgene Medicine | $15M | 28 Apr 2023 | Guangzhou, Guangdong, China | ||
Bioyond Tech | $30M | 03 Apr 2023 | Pudong, Shandong, China |
– OnQuality Pharmaceuticals LLC (“OnQuality”), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced the closing of its Series A+ financing round securing an additional $20 million in funding. This brings the total amount of capital raised in Series A and A+ to $35 million.
– This financing round included participation from Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, FreeS Fund, and additional biotech veterans.
– Proceeds from the financing will support the ongoing Phase II clinical trial of the company’s leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
OnQuality also announced the appointment of pharmaceutical executive Michael McCullar, Ph.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Rona Therapeutics | $35M | 19 Jul 2024 | Shanghai, Shanghai, China | ||
Brise Pharma | $20M | 22 Apr 2024 | Shanghai, Shanghai, China | ||
Shenluo Medical | 18 Apr 2024 | Hangzhou, Zhejiang, China | |||
Yuce Biotechnology | 22 Mar 2024 | Suzhou, Jiangsu, China | |||
OnCusp Therapeutics | $100M | 04 Jan 2024 | New York, New York, United States | ||
Salus BioMed | 01 Dec 2023 | Shenzhen, Guangdong, China | |||
Acchrom Tech | $15M | 29 May 2023 | Huairou, Beijing, China | ||
Reforgene Medicine | $15M | 28 Apr 2023 | Guangzhou, Guangdong, China | ||
Bioyond Tech | $30M | 03 Apr 2023 | Pudong, Shandong, China |
